Articles tagged with Bipolar Disorder
Researchers found that extended-release carbamazepine capsules improved symptoms in patients with bipolar disorder, including those experiencing mania and mixed episodes. The treatment was generally well-tolerated, with few adverse events reported.
A new study reveals that stress activates the mania-linked enzyme PKC, leading to impaired cognitive functions in the prefrontal cortex and reduced memory-related cell firing. Inhibiting PKC may offer a fast-acting treatment for mania, with potential benefits for patients seeking emergency room care.
PKC enzyme's excessive activity is associated with symptoms of bipolar disorder and schizophrenia. Increasing PKC activity in the prefrontal cortex impairs cognitive function, while inhibition may offer therapeutic benefits.
A new study found Seroquel to be effective in rapidly relieving core symptoms of depression, such as sadness and suicidal thoughts, in patients with rapid-cycling bipolar disorder. The treatment was also well-tolerated, with a low risk of mania compared to other treatments.
The BOLDER trial found SEROQUEL significantly reduces anxiety symptoms in bipolar depression patients within the first week of treatment. It also improves depressive symptoms and is well-tolerated with a favorable side effect profile.
A new study shows that Seroquel achieves remission in bipolar mania, with a significant increase in remission rates over time. The medication has been shown to be effective in reducing symptoms of racing thoughts, reckless behavior, and decreased sleep.
The BOLDER study found SEROQUEL to be superior to placebo in reducing depressive symptoms and anxiety in patients with bipolar disorder. Approximately 50% of patients achieved remission from their bipolar depression symptoms.
A Stanford study examined 42 college-age bipolar patients, finding significant improvement in symptoms and function with treatment. The research suggests that early and accurate diagnosis is crucial for preventing disease progression and that these young adults can function well if properly diagnosed and treated.
A new treatment approach combines a tailored medication regimen with the RAINBOW psychotherapy program to alleviate symptoms of bipolar disorder in children. The program has shown promising results, with 94% of children improving after treatment.
A double-blind study found that Risperdal significantly reduced 'manic' symptoms in patients with bipolar disorder, with treatment response achieved by 48% of patients taking Risperdal. The medication was also shown to improve depressive symptoms and was better tolerated than haloperidol.
Studies suggest schizophrenia and bipolar disorder have reduced expression of genes responsible for myelin development in brain cells, potentially linked to environmental issues or infections. This discovery may enable early treatment before symptoms emerge in late adolescence or early adulthood.
Research suggests that schizophrenia and bipolar disorder share similar genetic causes, with key oligodendrocyte-related and myelin-related genes showing reduced expression in patients. This finding has implications for understanding the underlying mechanisms of these complex mental health conditions.
A study published in the Journal of Clinical Psychiatry found that divalproex improved mood and behavioral disorders in over 78% of at-risk children. The medication may delay or prevent the onset of bipolar disorder, offering an alternative treatment option.
A mutation in the GRK3 gene, specifically in the promoter region, is linked to bipolar disorder in up to 10% of cases. The study suggests that this mutation causes individuals to become hypersensitive to dopamine, leading to mood extremes characteristic of the disease.
Seroquel was shown to significantly reduce mean Young Mania Rating Scale (YMRS) total scores in patients with bipolar disorder, with a faster reduction in symptoms compared to placebo. The medication was well-tolerated and had fewer side effects than other treatments like haloperidol.
Quetiapine has been shown to be statistically more effective at treating manic symptoms of bipolar disorder than placebo. The results of the clinical trials indicate rapid symptom improvement from day four and a favorable side effect profile, making it an exciting development in psychiatry.
The study presents data on quetiapine fumarate's efficacy in managing symptoms of acute mania in patients with bipolar disorder. The medication achieved significant responses in 48.1% of patients, with a high completion rate compared to the placebo group.
Researchers found lower concentrations of amino acid N-acetylaspartate in the right hippocampus of males with bipolar disorder. The study suggests a progressive nature of the disease, with decreasing levels of NAA seen over time.
Studies suggest atypical antipsychotics like Clozaril and Seroquel may have a protective effect against diabetes in patients with schizophrenia and bipolar disorder. Researchers recommend routine screening for diabetes, hypertension, and obesity in mentally ill patients.
A study published in the American Journal of Human Genetics has identified two overlapping genes on chromosome 13 as increasing susceptibility to bipolar disorder, affecting 2 million Americans. The same gene complex is also linked to an increased risk for schizophrenia.
Researchers studied 65 families with bipolar disorder and found strong genetic 'linkage' to specific regions on chromosomes 13 and 22, suggesting common genes contributing to both bipolar disorder and schizophrenia. These overlap genes may explain why the same anti-psychotic medications are effective treatments for both diseases.
AstraZeneca has submitted an application to the European Health Authorities for a new indication for Seroquel in treating manic episodes associated with bipolar disorder. The company's clinical trial programme showed strong and positive results, confirming Seroquel as an ideal first-line agent for this condition.
Quetiapine has delivered strong and positive results in treating acute mania associated with bipolar disorder, confirming its potential as an ideal first-line therapy. The medication also showed improved quality of life by minimizing side effects, making it a valuable treatment option for patients.
A new generation antipsychotic quetiapine, combined with mood stabilizers, shows improved efficacy in treating manic symptoms of bipolar disorder. The study results indicate that more patients experience full resolution of manic symptoms when treated with quetiapine.
Research suggests BDNF and NMDA receptor subunits are reduced in rats with early maternal deprivation, leading to changes in hippocampus function. This study provides evidence for the presence of molecular changes in the brain following exposure to stressful conditions during development.
Stanford researchers have established a link between creative genius and mental illness, with healthy artists showing more similarities in personality to individuals with manic depression. Emotional range was found to be a key factor in this relationship.
Scientists at Johns Hopkins Medicine found that panic disorder and manic depressive (bipolar) illness are likely related genetically and share a common cause. The study analyzed 203 families with bipolar disorder and identified symptoms of major mood disorders in relatives, showing a strong genetic link between the conditions.
A study led by Suppes is investigating whether supplementing bipolar patients' medications with acupuncture can help reduce medication use. The research aims to explore the potential benefits of acupuncture in treating depressive symptoms associated with bipolar disorder.
A new study published in Journal of Clinical Psychiatry found that a nutritional supplement called EM Power+ can successfully treat bipolar disorder. The supplement, developed by the Synergy Group of Canada, contains natural dietary minerals and vitamins.
A new study found that Topamax significantly reduced the severity of manic symptoms in patients with bipolar disorder, with 70% experiencing improvement. The medication was well-tolerated, with no significant weight gain and fewer side effects compared to traditional treatments.
A study by Professor Melissa DelBello found that quetiapine added to divalproex reduced psychotic symptoms in significantly more patients than divalproex alone. The quetiapine combination group also showed improved outcomes without treatment-emergent extrapyramidal symptoms.
A new report reveals that bipolar disorder costs the UK over £2 billion annually, with up to 85% associated with lost productivity. The study suggests Risperdal as an effective treatment for acute bipolar mania, improving symptoms by at least 50% in patients.
A large-scale study has found lamotrigine to be safe and effective in preventing episodes of mood swings in patients with rapid-cycling bipolar disorder. The study, published in Journal of Clinical Psychiatry, showed that 41% of patients who received lamotrigine remained stable without relapse for six months, compared to 26% on placebo.
Researchers at the University of Colorado at Boulder found that patients who received medication and a family-focused treatment program had fewer episodes of the disease, with longer delays before relapses. The study suggests that positive family interaction can help limit relapse rates.
Research at the University of Michigan found a 30% higher concentration of signaling cells in people with bipolar disorder, which could explain and treat manic depression. The discovery highlights the disorder's genetic and biological roots, offering new avenues for understanding and treatment.
A University of Illinois study found that over 50% of severely mentally ill Asian Americans sought help at culturally competent clinics within six months. Early treatment can improve outcomes, but educating community members about available services is crucial.
The Massachusetts General Hospital is leading a five-year, $20 million research study to improve the diagnosis and treatment of bipolar disorder. The study aims to evaluate existing treatment protocols and test new medications for the condition.
Scientists have confirmed a genetic connection to bipolar disorder by locating a gene on the long arm of human chromosome 18. This finding strengthens earlier research and could lead to better treatments and tests for the condition.